PMN · ProMIS Neurosciences, Inc.

ProMIS Neurosciences reported a net loss of $8.2 million for the first quarter of 2026, compared to a net loss of $7.3 million in the same period of 2025. The increased loss reflects higher research and development expenses associated with the ongoing PRECISE-AD Phase 1b clinical trial for PMN310, the company's lead Alzheimer's disease candidate. As of March 31, 2026, the company held $63.8 million in cash and cash equivalents, bolstered by the $75.5 million upfront proceeds from a private placement closed in February 2026. Management expects existing cash to fund operations through 2027, including completion of the Phase 1b trial. The company highlighted that the PRECISE-AD trial is fully enrolled with 144 participants and that a blinded interim analysis of safety and biomarker data is anticipated in early Q3 2026. This analysis, while not assessing efficacy, could provide early directional insights into target engagement. Top-line unblinded results are expected in early 2027. The company also noted the potential for an additional $100 million from warrant exercises as part of the financing. Management emphasized PMN310's differentiated mechanism of selectively targeting toxic amyloid-beta oligomers while sparing plaque, which may reduce ARIA risk compared to approved plaque-directed antibodies.